Please assess the completion status of the following clinical trial:

Trial Title: Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic lymphocytic leukemia:~* Previously treated patients of any age with a diagnosis of CLL with documented residual disease following therapy, but not meeting an indication for treatment based on current guidelines~* At least 2 months following previous CLL directed therapy~* ECOG performance status of less than or equal to 2 at study entry~* Laboratory test results within these ranges:~  * Platelet count greater than or equal to 50 x 109/L~ * CrCl \>.60 ml/min~ * Total bilirubin less than or equal to 1.5 mg/dL~ * AST (SGOT) and ALT (SGPT) less than or equal to 2 x ULN~* Females of childbearing must adhere to strict guidelines and have negative pregnancy test prior to enrollment~* Understand and voluntarily sign an informed consent form.~* Age greater than or equal to 18 years at the time of signing the informed consent form.~* Able to adhere to the study visit schedule and other protocol requirements.~* Disease free of prior malignancies for greater than or equal to 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.~* All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.~* Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin may use warfarin or low molecular weight heparin).~Exclusion Criteria:~* Known Hepatitis B Ag positive, Hepatitis C positive patients.~* Known HIV positive patients.~* Patients with uncontrolled Autoimmune Hemolytic Anemia (AIHA) or autoimmune thrombocytopenia (ITP)~* Patients with active fungal, bacterial, and/or viral infection~* Patients with known hypersensitivity to Revlimid or thalidomide~* Concurrent use of other anti-cancer agents or treatments~* Patients with history of deep venous thrombus or pulmonary embolism~* Patients who are at increased risk of thrombosis during treatment with Revlimid including those taking concurrent erythropoietin, darbepoetin or high-dose corticosteroids~* Inability to provide informed consent.~* Concurrent malignancy (excluding basal and squamous cell skin cancers).~* Pregnant or breast-feeding females. (Lactating females must agree not to breast feed while taking Revlimid).~* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.~* Use of any other experimental drug or therapy within 28 days of baseline.~* The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.~* Patients with a history of embolic events (e.g. TIA) from arrhythmia or peripheral arterial disease or of recent MI whether or not treated with anti-platelet drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy